Table I.
Treatment Arms | ||||
---|---|---|---|---|
ABVD (n=23) | Stanford V (n=21) | |||
N | % | N | % | |
Age (years) | 66 | 64 | ||
Median | ||||
Range | 61–83 | 60–83 | ||
Gender | ||||
Male | 11 | 49 | 13 | 63 |
Female | 12 | 52 | 8 | 38 |
ECOG PS | 6 | 26 | 9 | 43 |
0 | ||||
1 | 16 | 70 | 12 | 57 |
2 | 1 | 4 | . | . |
B symptoms | 12 | 52 | 11 | 52 |
No | ||||
Yes | 11 | 48 | 10 | 48 |
Disease Stage | 1 | 4 | 2 | 9 |
II | ||||
III | 17 | 74 | 13 | 62 |
IV | 5 | 22 | 6 | 29 |
Cell type | 2 | 9 | . | . |
NA | ||||
Nodular sclerosis | 11 | 48 | 11 | 52 |
Lymphocyte-rich | . | . | 1 | 5 |
Mixed cellularity | 7 | 30 | 4 | 19 |
Classical HL, NOS | 3 | 13 | 5 | 24 |
No. extra-nodal sites | 18 | 78 | 15 | 71 |
0 | ||||
1 | 3 | 13 | 4 | 19 |
2 | 2 | 9 | . | . |
4 | . | . | 1 | 5 |
5 | . | . | 1 | 5 |
Lung involvement | 21 | 91 | 18 | 86 |
No | ||||
Yes | 2 | 9 | 3 | 14 |
Liver involvement | 21 | 91 | 19 | 91 |
No | ||||
Yes | 2 | 9 | 2 | 9 |
Bone marrow involvement | 22 | 96 | 19 | 91 |
No | ||||
Yes | 1 | 4 | 2 | 9 |
Mediastinal involvement | 10 | 44 | 4 | 19 |
No | ||||
Yes | 13 | 56 | 17 | 81 |
IPS risk factors | . | . | 1 | 5 |
NA | ||||
1 | 4 | 17 | 2 | 9 |
2 | 10 | 44 | 10 | 48 |
3 | 7 | 30 | 2 | 9 |
4 | 2 | 9 | 1 | 5 |
5 | . | . | 4 | 19 |
6 | . | . | 1 | 5 |
Abbreviations: HL, Hodgkin lymphoma; NA, not available; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NOS, not otherwise specified; IPS, International Prognostic Score; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine.